Article
Oncology
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W. K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy
Summary: This study evaluated the efficacy of bevacizumab, alone or in combination with irinotecan, in recurrent glioblastoma patients. The results showed that bevacizumab, either alone or in combination, was well tolerated and active in treating recurrent glioblastoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Nimish A. Mohile, Hans Messersmith, Na Tosha Gatson, Andreas F. Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson, James Perry, Jana Portnow, David Schiff, Anne Shannon, Helen A. Shih, Roy Strowd, Martin van den Bent, Mateo Ziu, Jaishri Blakeley
Summary: This article provides guidance for therapy of diffuse astrocytic and oligodendroglial tumors in adults. Based on a systematic review of literature, the article provides recommendations for different tumor types and grades, including radiation therapy, chemotherapy, and other treatment options.
Article
Oncology
Adam S. Levy, Mark Krailo, Susan Chi, Doojduen Villaluna, Linda Springer, Chris Williams-Hughes, Maryam Fouladi, Amar Gajjar
Summary: The study compared the overall survival and event-free survival of different treatment regimens for recurrent MB in children. The addition of bevacizumab significantly reduced the risk of death and was relatively well tolerated. This suggests that the three-drug combination is worthy of further investigation.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Clinical Neurology
Catherine K. Gestrich, Marta E. Couce, Mark L. Cohen
Summary: The integration of histopathology, immunophenotyping, and molecular findings is profoundly changing the practice of diagnostic surgical neuropathology and enabling a more personalized approach to treating patients with gliomas. This is in anticipation of the upcoming fifth edition of CNS tumor classification.
Article
Oncology
Nimish A. Mohile, Hans Messersmith, Na Tosha Gatson, Andreas F. Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson, James Perry, Jana Portnow, David Schiff, Anne Shannon, Helen A. Shih, Roy Strowd, Martin van den Bent, Mateo Ziu, Jaishri Blakeley
Summary: This article provides guidance on the therapy for diffuse astrocytic and oligodendroglial tumors in adults. The recommendations are based on a systematic literature review and offer specific treatment options for different tumor grades, with reasonable alternatives. The article also provides treatment suggestions for specific patient populations.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Barbara Castelli, Carla Fonte, Milena Guidi, Marco Tellini, Marco Di Nicola, Alessandro Iacono, Anna Maria Buccoliero, Daniela Greto, Lorenzo Genitori, Iacopo Sardi
Summary: This article reports a case of recurrent low-grade glioma of the pineal region, in which the patient underwent multiple neurosurgical interventions, a carboplatin-etoposide regimen, and radiation treatment. The use of bevacizumab-irinotecan resulted in a stable response with no adverse events at one-year follow-up.
FRONTIERS IN ONCOLOGY
(2023)
Article
Clinical Neurology
Jonathan Metts, Brittany Harrington, Emad Salman, Scott M. Bradfield, Jennifer Flanary, Maua Mosha, Ernest Amankwah, Stacie Stapleton
Summary: The objective of the study was to determine the maximum tolerated dose (MTD) of escalating dose IT combined with a fixed dose of bevacizumab (BIT) in children with relapsed/refractory CNS tumors. Results showed that at the MTD, BIT therapy was well tolerated and prolonged treatment courses of up to 24 cycles were feasible, with radiographic responses observed. Further evaluation is needed for efficacy in a phase II trial.
CHILDS NERVOUS SYSTEM
(2022)
Article
Oncology
Hiroya Taniguchi, Kentaro Yamazaki, Toshiki Masuishi, Takeshi Kawakami, Yusuke Onozawa, Kazunori Honda, Shigenori Kadowaki, Yukiya Narita, Takahiro Tsushima, Satoshi Hamauchi, Akiko Todaka, Tomoya Yokota, Masashi Ando, Keita Mori, Hiromichi Shirasu, Hirofumi Yasui, Kei Muro
Summary: In this phase Ib study, trifluridine/tipiracil, irinotecan, and bevacizumab were tested in patients with metastatic colorectal cancer. The treatment showed moderate antitumor activity but had a high risk of severe myelotoxicity.
Article
Oncology
Georgios Papageorgiou, Sergios A. Tsakatikas, Rodanthi G. Fioretzaki, Christos Kosmas
Summary: Glioblastoma multiforme (GBM) is a malignant CNS disease with poor prognosis. Current treatment options have limited efficacy, prompting the need for new clinical trials. The VITb regimen has shown promising results in young patients with relapsed solid tumors and is discussed in the context of GBM treatment.
Article
Oncology
Wei Wei, Xiaohua Ban, Fan Yang, Jibin Li, Xiaqin Cheng, Rong Zhang, Xin Huang, Yongwen Huang, Qiaqia Li, Ya Qiu, Min Zheng, Xiaofeng Zhu, Jundong Li
Summary: This study investigated the therapeutic effect of anlotinib combined with monoclonal antibody intravenous injection on Chinese patients with endometrial cancer. The results showed that this combination treatment had a good efficacy and tolerable toxicity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B. Yurgelun, Douglas A. Rubinson, Deborah Schrag, Shaker R. Dakhil, Philip J. Stella, Douglas J. Weckstein, Donald B. Wender, Meredith Faggen, Tyler J. Zemla, Erica N. Heying, Samantha R. Schuetz, Stephanie Noble, Jeffrey A. Meyerhardt, Tanios Bekaii-Saab, Charles S. Fuchs, Kimmie Ng
Summary: The study investigated the efficacy of combining bevacizumab with irinotecan and cetuximab in patients with irinotecan-refractory metastatic colorectal cancer. Although there was no significant difference in progression-free survival between the two treatment groups, there was a statistically significant improvement in overall survival favoring the group that received bevacizumab in addition to irinotecan and cetuximab. Further investigation on this combination therapy is warranted.
Article
Oncology
Arndt Stahler, Dominik P. Modest, Ludwig Fischer von Weikersthal, Florian Kaiser, Thomas Decker, Swantje Held, Ullrich Graeven, Ingo Schwaner, Claudio Denzlinger, Michael Schenk, Annika Kurreck, Kathrin Heinrich, Clemens Giessen-Jung, Jens Neumann, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, Volker Heinemann
Summary: The XELAVIRI trial did not demonstrate non-inferiority overall, but sequential treatment showed non-inferiority in elderly patients and those with RAS mutant tumors.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Pharmacology & Pharmacy
B. Savran, M. F. Goc, F. U. Ozturk, A. O. Duran, O. Unal
Summary: The study investigated the diffusion restriction pattern and the relationship between ADC values and survival period in recurrent glial tumor patients treated with bevacizumab. The results showed that diffusion restriction appeared 2 to 6 months after treatment initiation and persisted for up to 24 months. The ADC values were negatively correlated with progression-free survival and overall survival, with patients having lower ADC values experiencing longer survival.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2023)
Article
Medicine, Research & Experimental
Veysel Haksoyler, Ali A Besen, Tolga Koseci, Polat Olgun, Ertugrul Bayram, Erkan Topkan
Summary: This study aimed to investigate the prognostic utility of pretreatment neutrophil-to-lymphocyte ratio (NLR) in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan. The results showed that patients with low NLR had significantly longer overall survival times than those with high NLR, indicating that NLR may serve as a novel biomarker for prognostic stratification in these patients.
BIOMARKERS IN MEDICINE
(2021)
Article
Oncology
Arndt Stahler, Volker Heinemann, Veronika Schuster, Kathrin Heinrich, Annika Kurreck, Clemens Giessen-Jung, Ludwig Fischer von Weikersthal, Florian Kaiser, Thomas Decker, Swantje Held, Ullrich Graeven, Ingo Schwaner, Claudio Denzlinger, Michael Schenk, Jens Neumann, Thomas Kirchner, Andreas Jung, Jorg Kumbrink, Sebastian Stintzing, Dominik P. Modest
Summary: This study demonstrated that consensus molecular subtypes (CMS) can serve as additional biomarkers for sequential versus initial combination therapy in treatment-naive metastatic colorectal cancer patients. CMS2 combined with RAS/BRAF wild-type status may be a potential predictor of benefit from initial combination therapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Hematology
Marion Alcantara, Caroline Houillier, Marie Blonski, Marie-Therese Rubio, Lise Willems, Agathe Waultier Rascalou, Magali Le Garff-Tavernier, Karim Maloum, Clotilde Bravetti, Laetitia Souchet, Damien Roos-Weil, Veronique Morel, Madalina Uzunov, Carole Metz, Meriem Dhib-Charfi, Stephanie Nguyen, Natalia Shor, Dimitri Psimaras, Nicolas Weiss, Nathalie Jacque, Silvia Solorzano, Nicolas Gauthier, Marie Le Cann, Francoise Norol, Carole Soussain, Sylvain Choquet
Article
Critical Care Medicine
Bertrand Mathon, Malory Favreau, Vincent Degos, Aymeric Amelot, Alexandre Le Joncour, Nicolas Weiss, Benjamin Rohaut, Loic Le Guennec, Anne-Laure Boch, Alexandre Carpentier, Franck Bielle, Karima Mokhtari, Ahmed Idbaih, Mehdi Touat, Alain Combes, Alexandre Demoule, Eimad Shotar, Vincent Navarro, Mathieu Raux, Sophie Demeret, Marc Pineton De Chambrun
Summary: Brain biopsy in critically ill patients with neurologic disease of unknown etiology is associated with high diagnostic yield, therapeutic modifications, and postbiopsy survival advantage. The safety profile seems acceptable in most patients. The benefit/risk ratio of brain biopsy in this population should be carefully weighted.
CRITICAL CARE MEDICINE
(2022)
Article
Biophysics
Laurence Schenone, Caroline Houillier, Marie Laure Tanguy, Sylvain Choquet, Kossi Agbetiafa, Herve Ghesquieres, Gandhi Damaj, Anna Schmitt, Krimo Bouabdallah, Guido Ahle, Remy Gressin, Jerome Cornillon, Roch Houot, Jean-Pierre Marolleau, Luc-Matthieu Fornecker, Olivier Chinot, Frederic Peyrade, Reda Bouabdallah, Cecile Molucon-Chabrot, Emmanuel Gyan, Adrien Chauchet, Olivier Casasnovas, Lucie Oberic, Vincent Delwail, Julie Abraham, Virginie Roland, Agathe Waultier-Rascalou, Lise Willems, Franck Morschhauser, Michel Fabbro, Renata Ursu, Catherine Thieblemont, Fabrice Jardin, Adrian Tempescul, Denis Malaise, Valerie Touitou, Lucia Nichelli, Magali Le Garff-Tavernier, Aurelie Plessier, Philippe Bourget, Caroline Bonmati, Sophie Wantz-Mezieres, Quentin Giordan, Veronique Dorvaux, Cyril Charron, Waliyde Jabeur, Khe Hoang-Xuan, Luc Taillandier, Carole Soussain
Summary: This study analyzed the therapeutic outcomes and treatment-related complications in PCNSL patients treated with IC-ASCT. It found that IC-ASCT is effective in first-line treatment and first-relapse PCNSL, and suggested that early application of ASCT and dose adjustment of IC could improve the benefit/risk ratio.
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Capucine Baldini, Nadia Younan, Eduardo Castanon Alvarez, Samy Ammari, Agusti Alentorn, Sarah Dumont, Jean-Sebastien Frenel, Anna-Luisa Di Stefano, Guillaume Louvel, Jean-Marie Michot, Rastislav Bahleda, Sophie Postel-Vinay, Andreea Varga, Aurelien Marabelle, Antoine Hollebecque, Franck Bielle, Khe Hoang-Xuan, Jean-Yves Delattre, Frederic Dhermain, Marc Sanson, Jean-Charles Soria, Ahmed Idbaih, Christophe Massard, Mehdi Touat
Summary: This study aimed to evaluate the benefit of molecular profiling in guiding the enrollment of patients with recurrent glioma in early phase trials. The results showed that molecularly-oriented patients had higher rates of disease stabilization and partial or complete response compared to non-molecularly-oriented patients. Molecular enrichment strategy was associated with longer overall survival.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Christelle Nilles, Daniel Delgadillo, Marie Sarazin, Lucia Nichelli, Karima Mokhtari, Bertrand Mathon, Sylvain Choquet, Loic Feuvret, Agusti Alentorn, Monica Ribeiro, Khe Hoang-Xuan, Caroline Houillier
Summary: This study described the neurocognition of patients with primary central nervous system lymphomas involving the corpus callosum (CC) and its posttherapeutic evolution. The study found that patients commonly experienced cognitive dysfunctions, especially memory impairment, and these impairments may only partially recover even after achieving complete response. Older age and splenium location were associated with poorer neurocognitive outcomes.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Khe Hoang-Xuan, Martina Deckert, Andres J. M. Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F. Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser, Patrick Roth, Roberta Ruda, Uwe Schlegel, Riccardo Soffietti, Carole Soussain, Martin J. B. Taphoorn, Valerie Touitou, Michael Weller, Jacoline E. C. Bromberg
Summary: The management of primary central nervous system lymphoma (PCNSL) is a controversial topic in neuro-oncology. The European Association of Neuro-Oncology (EANO) formed a multidisciplinary task force to update the evidence-based guidelines and include immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly.
Article
Infectious Diseases
Paul Petitgas, Pierre Tattevin, Alexandra Mailles, Pierre Fillatre, Jean-Paul Stahl
Summary: Encephalitis in elderly patients in France has a higher incidence rate, with a higher proportion of L. monocytogenes and VZV encephalitis, increased risk of mortality and long-term effects.
Article
Clinical Neurology
Macarena Villagran-Garcia, Sergio Muniz-Castrillo, Nicolas Lundahl Ciano-Petersen, Alberto Vogrig, Antonio Farina, Marine Villard, Dimitri Psimaras, Agusti Alentorn, David Goncalves, Nicole Fabien, Veronique Rogemond, Bastien Joubert, Jerome Honnorat
Summary: The link between renal cell and bladder cancer and paraneoplastic neurological syndromes (PNS) is rare and uncertain. This study clinically evaluated these associations and found that bladder cancer patients had higher detection rates of high-risk antibodies and higher certainty of PNS diagnosis.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Alexander Balcerac, Kevin Bihan, Dimitri Psimaras, Benedicte Lebrun-Vignes, Joe-Elie Salem, Nicolas Weiss
Summary: In this study, a disproportionality analysis was performed using the VigiBase database to identify drugs associated with PRES. A total of 73 drugs were found to be statistically associated with PRES. These results can assist clinicians in identifying potential drugs associated with PRES and making decisions regarding their discontinuation.
JOURNAL OF NEUROLOGY
(2023)
Letter
Oncology
Alice Laurenge, Renata Ursu, Emeline Tabouret, Vincent Harlay, Guido Ahle, Sylvain Choquet, Carole Soussain, Cecile Molucon-Chabrot, Bertrand Mathon, Karima Mokhtari, Valerie Pourcher, Lucia Nichelli, Stephane Marot, Mehdi Touat, Khe Hoang-Xuan, Caroline Houillier
LEUKEMIA & LYMPHOMA
(2023)
Review
Clinical Neurology
L. Nguyen-Them, A. Alentorn, G. Ahle, C. Soussain, B. Mathon, M. Le Garff Tavernier, C. Houillier, K. Hoang-Xuan
Summary: PCNSL is a highly aggressive non-Hodgkin lymphoma that affects the brain, spinal cord, eyes, and leptomeninges. Early diagnosis is crucial for effective management, but it can be challenging due to misleading radiological presentations, steroid response bias, and contraindications for brain biopsy. In this review, various CSF biomarkers for diagnosis and prognosis of PCNSL will be discussed, highlighting their advantages and limitations.
REVUE NEUROLOGIQUE
(2023)
Article
Clinical Neurology
Jeanne Benoit, Sergio Muniz-Castrillo, Alberto Vogrig, Antonio Farina, Anne-Laurie Pinto, Geraldine Picard, Veronique Rogemond, Deborah Guery, Agusti Alentorn, Dimitri Psimaras, Sylvain Rheims, Jerome Honnorat, Bastien Joubert
Summary: This study retrospectively analyzed the medical records of patients with positive CSF tests for anti-CASPR2 antibodies in our center between 2006 and 2020. It found that CASPR2-encephalitis has a heterogeneous onset and progression, with symptoms including seizures, memory disturbances, and neuropathic pain. Long-term follow-up showed that most patients achieved functional independence, but had slightly lower quality of life compared to the general population.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2023)
Article
Oncology
I. Hernandez-Verdin, E. Kirasic, K. Wienand, K. Mokhtari, S. Eimer, H. Loiseau, A. Rousseau, J. Paillassa, G. Ahle, F. Lerintiu, E. Uro-Coste, L. Oberic, D. Figarella-Branger, O. Chinot, G. Gauchotte, L. Taillandier, J. -P. Marolleau, M. Polivka, C. Adam, R. Ursu, A. Schmitt, N. Barillot, L. Nichelli, F. Lozano-Sanchez, M. -J. Ibanez-Julia, M. Peyre, B. Mathon, Y. Abada, F. Charlotte, F. Davi, C. Stewart, A. de Reynies, S. Choquet, C. Soussain, C. Houillier, B. Chapuy, K. Hoang-Xuan, A. Alenorn
Summary: Through comprehensive multi-omic analysis, we identified and characterized four molecular patterns in PCNSL, which have a distinct prognostic impact and can guide future clinical stratification and targeted interventions.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Isaias Hernandez-Verdin, Kadir C. Akdemir, Daniele Ramazzotti, Giulio Caravagna, Karim Labreche, Karima Mokhtari, Khe Hoang-Xuan, Matthieu Peyre, Franck Bielle, Mehdi Touat, Ahmed Idbaih, Alex Duval, Marc Sanson, Agusti Alentorn
Summary: This study reveals the presence of AID mutations at the pan-cancer level, with higher frequency in hematological cancers. AID mutational load is independently associated with a favorable outcome in immune-checkpoint inhibitors treated patients. Additionally, AID-related neoepitopes enhance immunogenicity and increase ICI sensitivity.
NPJ PRECISION ONCOLOGY
(2022)
Review
Clinical Neurology
Nicolas Lundahl Ciano-Petersen, Sergio Muniz-Castrillo, Cristina Birzu, Alberto Vogrig, Antonio Farina, Macarena Villagran-Garcia, Bastien Joubert, Dimitri Psimaras, Jerome Honnorat
Summary: This article provides an overview of the role of cytokines in autoimmune encephalitis and evaluates their suitability as clinical biomarkers. It also discusses the potential applicability and limitations of targeted immunotherapies based on associated antibodies in autoimmune encephalitis.
BRAIN COMMUNICATIONS
(2022)